Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9643616 | 0.84 | LMNA (0.48) | TSHRLMNA | |
| SCHEMBL329800 | 0.73 | — | — | |
| SCHEMBL6382360 | 0.73 | — | — | |
| SCHEMBL3221867 | 0.73 | — | — | |
| SCHEMBL5609579 | 0.73 | — | — | |
| SCHEMBL6971908 | 0.73 | — | — | |
| SCHEMBL4194140 | 0.73 | — | — | |
| SCHEMBL3982858 | 0.73 | — | — | |
| SCHEMBL144 | 0.69 | SLC6A2 (0.67) | DPP4F2TSHRHTR2ATAAR1 | |
| SCHEMBL448348 | 0.69 | DPP4 (0.53) | DPP4F2TSHRHTR2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 391 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4838934-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| EP-1042291-B1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2005-07-13 | — | — | EP | claimed |
| EP-0352953-B1 | Process for the preparation of purine derivatives | BEECHAM GROUP PLC (GB) | 2001-01-03 | — | — | EP | claimed |
| EP-1042291-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | claimed |
| WO-1999031064-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| EP-0165904-B1 | SUBSTITUTED BICYCLE COMPOUNDS | CIBA-GEIGY AG (CH) | 1991-04-10 | — | — | EP | claimed |
| CN-113149883-B | Process for preparing pyrrole compounds | 武田药品工业株式会社 | 2024-04-02 | — | — | CN | disclosed |
| US-20230322669-A1 | METHOD FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| EP-4257577-A2 | METHOD FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2023-10-11 | — | — | EP | disclosed |
| US-11649206-B2 | Method for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-16 | — | — | US | disclosed |
| US-20230143246-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-23 | — | — | US | disclosed |
| US-20220411449-A1 | Method for Preparing Heteroleptic Triarylbismuthanes and Compounds Produced by the Same | UNIVERSITY OF HAWAII | 2022-12-29 | — | — | US | disclosed |
| EP-0101602-A1 | Derivatives of 7-oxo-4-oxa-diazabicyclo-(3.2.0)-hept-2-en not substituted in position 6, processes for their preparation and their use as intermediates in the synthesis of beta-lactam antibiotics | BAYER AG (DE) | 1984-02-29 | — | — | EP | disclosed |
| US-4313945-A | 7-Thiazolyl-acetamido-cephem derivatives with terminal aminocarboxylic acid grouping | CIBA-GEIGY CORPORATION (US) | 1982-02-02 | — | — | US | disclosed |
| US-4304718-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-12-08 | — | — | US | disclosed |
| EP-0038758-A1 | Amino-acids derivatives and their therapeutic use | SOCIETE CIVILE BIOPROJET (FR) | 1981-10-28 | — | — | EP | disclosed |
| EP-0016296-A1 | Cephalosporin derivatives, process for their preparation, compositions containing them, and intermediates and their preparation | CIBA-GEIGY AG (CH) | 1980-10-01 | — | — | EP | disclosed |
| US-4181800-A | ANTIBIOTICS FROM SUBSTITUTED PERHYDRO-S-TRIAZINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-01-01 | — | — | US | disclosed |
| EP-0000952-A1 | Benzhydryl guanidine derivatives and pharmaceutical compositions | McNeilab, Inc. (US) | 1979-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411449-A1 | Method for Preparing Heteroleptic Triarylbismuthanes and Compounds Produced by the Same | COASY, HAGH, MRM1 | DPP4 2102/4885F2 3670/4885TSHR 2421/4885 |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | DPP4 6/4885F2 2034/4885TSHR 1513/4885 |
| US-20230143246-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | OTC, SLC38A7, SRI | DPP4 3644/4885F2 878/4885TSHR 3089/4885 |
| US-20230322669-A1 | METHOD FOR PRODUCING PYRROLE COMPOUND | HPD, PPOX, CBR3 | DPP4 2141/4885F2 147/4885TSHR 1913/4885 |
| US-11649206-B2 | Method for producing pyrrole compound | HPD, PPOX, CBR3 | DPP4 2141/4885F2 147/4885TSHR 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.